查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2035233

伴隨診斷市場預測至2034年－按產品和服務、技術、適應症、檢體類型、應用、最終用戶和地區分類的全球分析

Companion Diagnostics Market Forecasts to 2034 - Global Analysis By Product & Services, Technology, Indication, Sample Type, Application, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球伴隨診斷市場規模將達到 104 億美元，並在預測期內以 14.2% 的複合年成長率成長，到 2034 年將達到 301 億美元。

伴隨診斷是指能夠提供相應藥物和生物製藥安全性和有效性關鍵資訊的醫療設備和檢測方法，使醫療專業人員能夠判斷特定治療方法是否適用於特定患者。這些檢測方法可以識別預測治療反應的特定生物標記、基因突變或蛋白質表現。隨著精準醫療和標靶治療的興起，腫瘤學和其他治療領域正在經歷變革，伴隨診斷已成為全球現代藥物研發和臨床實踐中不可或缺的一部分。

癌症和慢性疾病發生率上升

全球癌症和慢性疾病負擔持續加重，推動了對標靶治療結合伴隨診斷以最佳化治療方法方案的需求激增。腫瘤學仍然是伴隨診斷的主要應用領域，伴隨診斷有助於識別更有可能對特定免疫療法或激酶抑制劑產生反應的患者，從而避免不必要的副作用和醫療成本。隨著慢性疾病日益複雜，以往「一刀切」的治療方法正逐漸轉向以生物標記主導的策略。這種轉變迫使製藥公司在開發新型療法的同時開發伴隨診斷，並隨著監管機構日益要求在精準醫療核准中納入此類檢測，推動了市場擴張。

高昂的開發成本和複雜的監管規定

伴隨診斷的開發和商業化需要大量的資金投入，並且需要應對複雜的監管流程，這可能會延緩產品上市。製造商必須檢驗檢測方法與相應藥物的聯合有效性，這涉及協調臨床試驗並證明其分析和臨床效用。不同地區的法規結構（例如FDA和EMA的要求）增加了合規負擔，並延長了產品上市時間。中小診斷公司往往缺乏滿足這些要求的資源，導致競爭和創新有限。這些挑戰導致產品成本增加，最終轉嫁給醫療保健系統，即使臨床效益顯而易見，也可能限制患者獲得這些產品的機會。

非侵入性檢測中液態生物檢體的進展

新型液態生物檢體技術透過簡單的血液採樣即可進行伴隨診斷檢測，取代了侵入性組織切片檢查，從而創造了巨大的機會。這種方法可以捕獲循環腫瘤DNA和其他生物標記物，無需重複手術即可即時監測治療反應並檢測抗藥性突變。液態生物檢體對於難以取得的腫瘤或病情過於嚴重而無法進行傳統切片檢查的患者尤其有用。隨著靈敏度和特異性的不斷提高，這些檢測方法正在將伴隨診斷的範圍擴展到早期癌症檢測和微量殘存疾病監測等新領域，從而在傳統治療方法方案之外開闢出重要的收入來源。

醫療保健計劃報銷方面的不確定性

不一致且不斷變化的報銷政策對伴隨診斷的廣泛應用構成嚴重威脅，因為保險公司可能不會承保缺乏明確經濟效益的檢測。儘管監管機構越來越強制要求某些藥物進行伴隨診斷，但報銷決定往往滯後，導致市場准入差異。私人保險公司和公共醫療系統對檢測的成本效益評估標準不同，導致患者在獲得檢測方面存在區域性差異。生物標記的快速發現速度超過了衛生技術評估機構制定保險覆蓋政策的能力，導致等待檢測結果的患者治療延誤。這些不確定性阻礙了對檢測研發的投資。

新冠疫情的影響：

新冠疫情對伴隨診斷市場產生了雙重影響。疫情初期，它擾亂了臨床試驗和非緊急檢測，但隨後加速了精準醫療的普及。檢查室關閉和資源重新分配給新冠病毒檢測，延緩了伴隨診斷的研發項目，並減少了患者接受常規癌症篩檢的機會。然而，疫情也展現了快速分子診斷和分散式檢查模式的有效性，刺激了對適用於伴隨診斷平台的投資。人們對個人化醫療方法的認知不斷提高，加上遠距遠端醫療和居家檢體採集的普及，推動了基礎設施的持續改進，這將有助於後疫情時代伴隨診斷的廣泛應用。

在預測期內，組織檢體市場預計將佔據最大的市場佔有率。

預計在預測期內，組織檢體市場將佔據最大的市場佔有率。這反映了組織切片檢查長期以來作為生物標記分析金標準的地位。福馬林固定、石蠟包埋的組織塊仍然是免疫組織化學和基於次世代定序(NGS) 的伴隨診斷的首選檢體類型，這一趨勢在腫瘤學領域尤為顯著，因為腫瘤結構和細胞微環境至關重要。領先的製藥公司已檢驗了多種針對固體癌（包括肺癌、乳癌和結直腸癌）藥物的基於組織的伴隨診斷方法。病理檢查室的廣泛應用以及組織檢測保險報銷機制的完善，將進一步鞏固該細分市場在整個預測期內的主導地位。

在預測期內，「個人化治療選擇」細分市場預計將呈現最高的複合年成長率。

在預測期內，「個人化治療選擇」細分市場預計將呈現最高的成長率，這主要得益於標靶治療方案在腫瘤以外的多個疾病領域的擴展。此應用透過基於患者特異性生物標記譜直接匹配最有效的藥物，最大限度地減少了試試驗處方和不利事件。多組體學技術的進步使得同時評估數百種生物標記成為可能，從而建立出全面的治療流程。製藥公司正日益圍繞伴隨診斷構建其藥物研發項目，以預先識別可能對治療產生反應的患者群體，從而加速監管核准和市場准入。隨著精準醫療滲透到循環系統、神經系統和感染疾病領域，個人化治療選擇正成為成長最快的應用領域。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其強大的醫療保健基礎設施、高額的藥品研發投入以及有利的法規結構。美國憑藉FDA的藥品核准和伴隨診斷的平行核准流程處於主導，為產品進入市場開闢了高效的途徑。公共和私人保險公司提供的強大保險覆蓋範圍，以及基因組檢測在臨床實踐中的廣泛應用，正在推動其普及。總部位於該地區的領先診斷和製藥公司正持續投資於新型生物標記的發現和新檢測方法的開發。此外，患者對精準醫療益處的認知不斷提高，也將進一步鞏固北美市場在整個預測期內的主導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於快速發展的醫療保健體系、龐大的患者群體以及政府對精準醫療舉措不斷成長的投入。中國、日本、印度和韓國等國家正在擴展其分子診斷基礎設施，並實施國家級基因組醫學計畫。癌症和慢性病的盛行率上升，以及製藥業在該地區日益成長的影響力，正在催生對伴隨診斷檢測的巨大需求。臨床試驗中較低的人事費用和營運成本吸引了國際贊助商，進一步將亞太地區融入全球藥物研發網路。隨著監管協調的推進和醫療保健支出的成長，該地區正在成為伴隨診斷領域成長最快的市場。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章：全球伴隨診斷市場：依產品與服務分類

  • 產品
    • 檢測方法、試劑盒、試劑
    • 設備和系統
    • 軟體和生物資訊學工具
  • 服務
    • 發展服務
    • 分析和臨床檢驗服務
    • 監理和核准服務
    • 合約研究服務

第6章 全球伴隨診斷市場：依技術分類

  • 聚合酵素鏈鎖反應（PCR）
  • 次世代定序（NGS）
  • 免疫組織化學（IHC）
  • 原位雜合反應（ISH）
  • 微陣列
  • 數位PCR
  • 其他新興技術

第7章 全球伴隨診斷市場：依適應症分類

  • 腫瘤學
    • 肺癌
    • 乳癌
    • 結腸癌
    • 黑色素瘤
    • 胃癌
    • 其他癌症
  • 心血管疾病
  • 神經系統疾病
  • 感染疾病
  • 自體免疫/發炎性疾病
  • 其他改編

第8章 全球伴隨診斷市場：依樣本類型分類

  • 組織樣本
  • 血液檢體（液態切片）
  • 唾液樣本
  • 尿液檢體
  • 其他檢體類型

第9章 全球伴隨診斷市場：依應用分類

  • 患者分層
  • 藥物療效監測
  • 安全性和毒性分析
  • 生物標記鑑定
  • 個人化治療方案

第10章：全球伴隨診斷市場：依最終用戶分類

  • 醫院
  • 診斷檢查室
  • 製藥和生物技術公司
  • 受託研究機構（CRO）
  • 學術研究機構
  • 其他最終用戶

第11章 全球伴隨診斷市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第12章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第13章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第14章：公司簡介

  • F Hoffmann La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Qiagen NV
  • Illumina Inc.
  • Danaher Corporation
  • BioMerieux SA
  • Siemens Healthineers AG
  • Myriad Genetics Inc.
  • Guardant Health Inc.
  • Exact Sciences Corporation
  • Foundation Medicine Inc.
  • Sysmex Corporation
  • Bio Rad Laboratories Inc.
Product Code: SMRC35652

According to Stratistics MRC, the Global Companion Diagnostics Market is accounted for $10.4 billion in 2026 and is expected to reach $30.1 billion by 2034 growing at a CAGR of 14.2% during the forecast period. Companion diagnostics are medical devices or tests that provide essential information about the safety and effectiveness of a corresponding drug or biological product, enabling healthcare providers to determine whether a particular therapeutic treatment is appropriate for an individual patient. These tests identify specific biomarkers, genetic mutations, or protein expressions that predict treatment response. The growing emphasis on precision medicine and targeted therapies is transforming oncology and other therapeutic areas, making companion diagnostics an integral component of modern drug development and clinical practice worldwide.

Market Dynamics:

Driver:

Rising prevalence of cancer and chronic diseases

The global burden of cancer and chronic conditions continues to escalate, creating urgent demand for targeted therapies paired with companion diagnostics that optimize treatment selection. Oncology remains the dominant application area, with companion tests identifying patients likely to respond to specific immunotherapies or kinase inhibitors, thereby avoiding unnecessary side effects and healthcare costs. As chronic diseases become increasingly complex, one-size-fits-all approaches are giving way to biomarker-driven strategies. This shift is compelling pharmaceutical companies to develop companion diagnostics alongside novel therapeutics, driving market expansion as regulatory agencies increasingly require such tests for approval of precision medicines.

Restraint:

High development costs and regulatory complexities

Developing and commercializing companion diagnostics involves substantial financial investment and navigating intricate regulatory pathways that delay market entry. Manufacturers must simultaneously validate their test with the corresponding drug, requiring coordinated clinical trials and demonstrating both analytical and clinical utility. Different regulatory frameworks across regions, such as FDA and EMA requirements, create additional compliance burdens and increase time-to-market. Smaller diagnostic companies often lack resources to meet these demands, limiting competition and innovation. These challenges result in higher product costs, which are eventually passed to healthcare systems, potentially restricting patient access despite clear clinical benefits.

Opportunity:

Liquid biopsy advancements for non-invasive testing

Emerging liquid biopsy technologies are creating significant opportunities by enabling companion diagnostic testing from simple blood draws instead of invasive tissue biopsies. This approach captures circulating tumor DNA and other biomarkers, allowing real-time monitoring of treatment response and detection of resistance mutations without repeated surgical procedures. Liquid biopsies are particularly valuable for hard-to-access tumors and for patients too ill for traditional biopsies. As sensitivity and specificity continue to improve, these tests are expanding companion diagnostics into new applications, including early cancer detection and minimal residual disease monitoring, opening substantial revenue streams beyond conventional treatment selection.

Threat:

Reimbursement uncertainties across healthcare systems

Inconsistent and evolving reimbursement policies pose a serious threat to widespread adoption of companion diagnostics, as payers may not cover tests lacking clear economic evidence. While regulators increasingly mandate companion diagnostics for certain drugs, reimbursement decisions often lag behind, creating market access gaps. Private insurers and public healthcare systems evaluate the cost-effectiveness of testing differently, leading to geographic disparities in patient access. The rapid pace of biomarker discovery outstrips the ability of health technology assessment bodies to establish coverage policies, causing treatment delays for patients awaiting test results. These uncertainties discourage investment in test development.

Covid-19 Impact:

The COVID-19 pandemic had a dual impact on the companion diagnostics market, initially disrupting clinical trials and non-urgent testing while later accelerating precision medicine adoption. Laboratory shutdowns and redeployment of resources toward COVID-19 testing delayed companion diagnostic development programs and reduced patient access to routine cancer testing. However, the pandemic also demonstrated the power of rapid molecular diagnostics and decentralized testing models, driving investment in platforms applicable to companion testing. Increased awareness of personalized approaches to healthcare, combined with telemedicine expansion and home-based sample collection, has created lasting infrastructure improvements that benefit companion diagnostics adoption in the post-pandemic era.

The Tissue Samples segment is expected to be the largest during the forecast period

The Tissue Samples segment is expected to account for the largest market share during the forecast period, reflecting the longstanding gold standard status of tissue biopsies for biomarker analysis. Formalin-fixed paraffin-embedded tissue blocks remain the preferred sample type for immunohistochemistry and next-generation sequencing-based companion tests, particularly in oncology where tumor architecture and cellular context are critical. Major pharmaceutical companies have validated numerous tissue-based companion diagnostics for drugs targeting solid tumors, including lung, breast, and colorectal cancers. The extensive installed base of pathology laboratories and established reimbursement pathways for tissue testing further reinforce this segment's dominance throughout the forecast timeline.

The Personalized Treatment Selection segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Personalized Treatment Selection segment is predicted to witness the highest growth rate, driven by the expanding arsenal of targeted therapies across multiple disease areas beyond oncology. This application directly matches patients with the most effective drug based on their unique biomarker profile, minimizing trial-and-error prescribing and adverse events. Advances in multi-omics technologies enable simultaneous assessment of hundreds of biomarkers, allowing comprehensive treatment algorithms. Pharmaceutical companies increasingly structure drug development programs around companion diagnostics that prospectively identify responsive patient populations, accelerating regulatory approval and market adoption. As precision medicine penetrates cardiology, neurology, and infectious diseases, personalized treatment selection becomes the fastest-growing application.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by robust healthcare infrastructure, high pharmaceutical R&D spending, and favorable regulatory frameworks. The United States leads in companion diagnostic approvals through the FDA's simultaneous review process alongside drug approvals, creating a streamlined pathway for market entry. Strong reimbursement coverage from public and private payers, combined with widespread adoption of genomic testing in clinical practice, drives utilization. Major diagnostic manufacturers and pharmaceutical companies headquartered in the region continuously invest in novel biomarker discovery and test development. Patient awareness of precision medicine benefits further accelerates North American market dominance throughout the forecast period.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, propelled by rapidly improving healthcare systems, large patient populations, and increasing government investments in precision medicine initiatives. Countries including China, Japan, India, and South Korea are expanding molecular diagnostics infrastructure and implementing national genomic medicine programs. Rising prevalence of cancer and chronic diseases, coupled with growing pharmaceutical industry presence in the region, creates substantial demand for companion diagnostic testing. Lower labor and operational costs for clinical trials attract international sponsors, further integrating Asia Pacific into global drug development networks. As regulatory harmonization progresses and healthcare spending increases, this region emerges as the fastest-growing market for companion diagnostics.

Key players in the market

Some of the key players in Companion Diagnostics Market include F Hoffmann La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Agilent Technologies Inc., Qiagen NV, Illumina Inc., Danaher Corporation, BioMerieux SA, Siemens Healthineers AG, Myriad Genetics Inc., Guardant Health Inc., Exact Sciences Corporation, Foundation Medicine Inc., Sysmex Corporation and Bio Rad Laboratories Inc.

Key Developments:

In March 2026, Roche announced the expansion of its digital pathology portfolio, integrating AI-driven algorithms to enhance the accuracy of HER2 and PD-L1 biomarker interpretation in oncology, supporting its market-leading companion diagnostics on the VENTANA platform.

In March 2026, Abbott announced that its acquisition of Exact Sciences, valued at over $30 billion, is on track to close in Q2 2026. This move integrates market-leading precision oncology diagnostics (Cologuard and Oncotype DX) into Abbott's portfolio.

In August 2025, Thermo Fisher received CE-IVDR certification for its Oncomine Dx Target Test, expanding its use in Europe to aid in the selection of therapies for patients with advanced non-small cell lung cancer (NSCLC) and cholangiocarcinoma.

Product & Services Covered:

  • Product
  • Services

Technologies Covered:

  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • In Situ Hybridization (ISH)
  • Microarrays
  • Digital PCR
  • Other Emerging Technologies

Indications Covered:

  • Oncology
  • Cardiovascular Diseases
  • Neurological Disorders
  • Infectious Diseases
  • Autoimmune & Inflammatory Diseases
  • Other Indications

Sample Types Covered:

  • Tissue Samples
  • Blood Samples (Liquid Biopsy)
  • Saliva Samples
  • Urine Samples
  • Other Sample Types

Applications Covered:

  • Patient Stratification
  • Drug Efficacy Monitoring
  • Safety & Toxicity Profiling
  • Biomarker Identification
  • Personalized Treatment Selection

End Users Covered:

  • Hospitals
  • Diagnostic Laboratories
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Academic & Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Companion Diagnostics Market, By Product & Services

  • 5.1 Products
    • 5.1.1 Assays, Kits & Reagents
    • 5.1.2 Instruments/Systems
    • 5.1.3 Software & Bioinformatics Tools
  • 5.2 Services
    • 5.2.1 Development Services
    • 5.2.2 Analytical & Clinical Validation Services
    • 5.2.3 Regulatory & Approval Services
    • 5.2.4 Contract Research Services

6 Global Companion Diagnostics Market, By Technology

  • 6.1 Polymerase Chain Reaction (PCR)
  • 6.2 Next-Generation Sequencing (NGS)
  • 6.3 Immunohistochemistry (IHC)
  • 6.4 In Situ Hybridization (ISH)
  • 6.5 Microarrays
  • 6.6 Digital PCR
  • 6.7 Other Emerging Technologies

7 Global Companion Diagnostics Market, By Indication

  • 7.1 Oncology
    • 7.1.1 Lung Cancer
    • 7.1.2 Breast Cancer
    • 7.1.3 Colorectal Cancer
    • 7.1.4 Melanoma
    • 7.1.5 Gastric Cancer
    • 7.1.6 Other Cancers
  • 7.2 Cardiovascular Diseases
  • 7.3 Neurological Disorders
  • 7.4 Infectious Diseases
  • 7.5 Autoimmune & Inflammatory Diseases
  • 7.6 Other Indications

8 Global Companion Diagnostics Market, By Sample Type

  • 8.1 Tissue Samples
  • 8.2 Blood Samples (Liquid Biopsy)
  • 8.3 Saliva Samples
  • 8.4 Urine Samples
  • 8.5 Other Sample Types

9 Global Companion Diagnostics Market, By Application

  • 9.1 Patient Stratification
  • 9.2 Drug Efficacy Monitoring
  • 9.3 Safety & Toxicity Profiling
  • 9.4 Biomarker Identification
  • 9.5 Personalized Treatment Selection

10 Global Companion Diagnostics Market, By End User

  • 10.1 Hospitals
  • 10.2 Diagnostic Laboratories
  • 10.3 Pharmaceutical & Biotechnology Companies
  • 10.4 Contract Research Organizations (CROs)
  • 10.5 Academic & Research Institutes
  • 10.6 Other End Users

11 Global Companion Diagnostics Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Certifications
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 F Hoffmann La Roche Ltd
  • 14.2 Thermo Fisher Scientific Inc.
  • 14.3 Abbott Laboratories
  • 14.4 Agilent Technologies Inc.
  • 14.5 Qiagen NV
  • 14.6 Illumina Inc.
  • 14.7 Danaher Corporation
  • 14.8 BioMerieux SA
  • 14.9 Siemens Healthineers AG
  • 14.10 Myriad Genetics Inc.
  • 14.11 Guardant Health Inc.
  • 14.12 Exact Sciences Corporation
  • 14.13 Foundation Medicine Inc.
  • 14.14 Sysmex Corporation
  • 14.15 Bio Rad Laboratories Inc.

List of Tables

  • Table 1 Global Companion Diagnostics Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Companion Diagnostics Market Outlook, By Product & Services (2023-2034) ($MN)
  • Table 3 Global Companion Diagnostics Market Outlook, By Products (2023-2034) ($MN)
  • Table 4 Global Companion Diagnostics Market Outlook, By Assays, Kits & Reagents (2023-2034) ($MN)
  • Table 5 Global Companion Diagnostics Market Outlook, By Instruments / Systems (2023-2034) ($MN)
  • Table 6 Global Companion Diagnostics Market Outlook, By Software & Bioinformatics Tools (2023-2034) ($MN)
  • Table 7 Global Companion Diagnostics Market Outlook, By Services (2023-2034) ($MN)
  • Table 8 Global Companion Diagnostics Market Outlook, By Development Services (2023-2034) ($MN)
  • Table 9 Global Companion Diagnostics Market Outlook, By Analytical & Clinical Validation Services (2023-2034) ($MN)
  • Table 10 Global Companion Diagnostics Market Outlook, By Regulatory & Approval Services (2023-2034) ($MN)
  • Table 11 Global Companion Diagnostics Market Outlook, By Contract Research Services (2023-2034) ($MN)
  • Table 12 Global Companion Diagnostics Market Outlook, By Technology (2023-2034) ($MN)
  • Table 13 Global Companion Diagnostics Market Outlook, By Polymerase Chain Reaction (PCR) (2023-2034) ($MN)
  • Table 14 Global Companion Diagnostics Market Outlook, By Next-Generation Sequencing (NGS) (2023-2034) ($MN)
  • Table 15 Global Companion Diagnostics Market Outlook, By Immunohistochemistry (IHC) (2023-2034) ($MN)
  • Table 16 Global Companion Diagnostics Market Outlook, By In Situ Hybridization (ISH) (2023-2034) ($MN)
  • Table 17 Global Companion Diagnostics Market Outlook, By Microarrays (2023-2034) ($MN)
  • Table 18 Global Companion Diagnostics Market Outlook, By Digital PCR (2023-2034) ($MN)
  • Table 19 Global Companion Diagnostics Market Outlook, By Other Emerging Technologies (2023-2034) ($MN)
  • Table 20 Global Companion Diagnostics Market Outlook, By Indication (2023-2034) ($MN)
  • Table 21 Global Companion Diagnostics Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 22 Global Companion Diagnostics Market Outlook, By Lung Cancer (2023-2034) ($MN)
  • Table 23 Global Companion Diagnostics Market Outlook, By Breast Cancer (2023-2034) ($MN)
  • Table 24 Global Companion Diagnostics Market Outlook, By Colorectal Cancer (2023-2034) ($MN)
  • Table 25 Global Companion Diagnostics Market Outlook, By Melanoma (2023-2034) ($MN)
  • Table 26 Global Companion Diagnostics Market Outlook, By Gastric Cancer (2023-2034) ($MN)
  • Table 27 Global Companion Diagnostics Market Outlook, By Other Cancers (2023-2034) ($MN)
  • Table 28 Global Companion Diagnostics Market Outlook, By Cardiovascular Diseases (2023-2034) ($MN)
  • Table 29 Global Companion Diagnostics Market Outlook, By Neurological Disorders (2023-2034) ($MN)
  • Table 30 Global Companion Diagnostics Market Outlook, By Infectious Diseases (2023-2034) ($MN)
  • Table 31 Global Companion Diagnostics Market Outlook, By Autoimmune & Inflammatory Diseases (2023-2034) ($MN)
  • Table 32 Global Companion Diagnostics Market Outlook, By Other Indications (2023-2034) ($MN)
  • Table 33 Global Companion Diagnostics Market Outlook, By Sample Type (2023-2034) ($MN)
  • Table 34 Global Companion Diagnostics Market Outlook, By Tissue Samples (2023-2034) ($MN)
  • Table 35 Global Companion Diagnostics Market Outlook, By Blood Samples (Liquid Biopsy) (2023-2034) ($MN)
  • Table 36 Global Companion Diagnostics Market Outlook, By Saliva Samples (2023-2034) ($MN)
  • Table 37 Global Companion Diagnostics Market Outlook, By Urine Samples (2023-2034) ($MN)
  • Table 38 Global Companion Diagnostics Market Outlook, By Other Sample Types (2023-2034) ($MN)
  • Table 39 Global Companion Diagnostics Market Outlook, By Application (2023-2034) ($MN)
  • Table 40 Global Companion Diagnostics Market Outlook, By Patient Stratification (2023-2034) ($MN)
  • Table 41 Global Companion Diagnostics Market Outlook, By Drug Efficacy Monitoring (2023-2034) ($MN)
  • Table 42 Global Companion Diagnostics Market Outlook, By Safety & Toxicity Profiling (2023-2034) ($MN)
  • Table 43 Global Companion Diagnostics Market Outlook, By Biomarker Identification (2023-2034) ($MN)
  • Table 44 Global Companion Diagnostics Market Outlook, By Personalized Treatment Selection (2023-2034) ($MN)
  • Table 45 Global Companion Diagnostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 46 Global Companion Diagnostics Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 47 Global Companion Diagnostics Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 48 Global Companion Diagnostics Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)
  • Table 49 Global Companion Diagnostics Market Outlook, By Contract Research Organizations (CROs) (2023-2034) ($MN)
  • Table 50 Global Companion Diagnostics Market Outlook, By Academic & Research Institutes (2023-2034) ($MN)
  • Table 51 Global Companion Diagnostics Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.